Roles
- Assiociate Professor of Clinical
-
Biography
Dr. Danielle Shpiner joined the Department of Neurology as an Assistant Professor of Clinical Neurology in 2019. She is originally from Buffalo, New York. She attended college at Johns Hopkins University where she majored in Neuroscience. She graduated from Boston University School of Medicine and completed her internship and residency in Neurology at the University of Miami. In her final year of residency, she served as Chief Resident of Research and Education. She completed her fellowship in Movement Disorders at the University of Miami. -
Education & Training
Education
Licensures and Certifications
-
Publications
Disclaimer: Information presented in this section has been consolidated using AI and machine learning technologies. While every effort has been made to ensure accuracy, errors may occur. If you identify any inaccuracies, use this link to inform our data team. Your feedback is appreciated and helps us improve the quality of our content.
Clinical Trials
Viewing 0 of 2 clinical trials.
-
This is a randomized, double-blind, placebo-controlled study to assess the efficacy, safety, and PK of FNP-223 in adult participants with PSP.The planned FNP-223 dose to be studied is 300 mg administered orally (PO), 3 times daily (TID), recommended every 8 hours.The study will consist of an up to 42-day screening period (screening period will have a window of -7 days to -42 days), a 52-week treatment period, and a 4-week post-treatment follow-up.
- Principal Investigator: Danielle Shpiner
- Study Phase: TBD
- Enrollment Status: Open
-
This is a Phase 2, double-blind, multi-center, randomized, placebo-controlled trial to evaluate the safety, tolerability, and exploratory efficacy of three different doses of IkT-148009 self-administered once daily (QD) with food for 12 weeks in patients with untreated Parkinsons Disease (PD). The main purpose of this research study is to learn more about how safe IkT-148009 is in patients with PD at 2 different doses. The objective is to identify the following:•Minimum safe does•Maximum safe tolerated dose•Evaluate efficacy
- Principal Investigator: Danielle Shpiner
- Study Phase: TBD
- Enrollment Status: Closed